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ABSTRACT 
EFFECTS OF DEVELOPMENTAL EXPOSURES OF TWO EMERGING 
ENVIRONMENTAL TOXICANTS ON ESTROGEN-SENSITIVE ENDPOINTS 
MAY 2015 
CORINNE E. HILL, B.S., UNIVERSITY OF ALBANY 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Laura N. Vandenberg 
 
 
Background: Humans have created thousands of synthetic chemicals that are released 
into the environment, causing widespread exposures of wildlife and humans alike. Some 
of these chemicals are known to disrupt one or more aspects of hormone action, with a 
subset inducing abnormalities in endocrine related tissues and organs such as the 
reproductive system. Bisphenol S (BPS) and tetrabromobisphenol A (TBBPA) are two 
chemicals commonly used in consumer products and are suspected to have endocrine 
disrupting properties based on their similar chemical structures to known endocrine 
disrupting chemicals (EDCs).   
Objectives:  To determine whether perinatal exposure to BPS or TBBPA induced 
abnormalities in ovarian and uterine tissue at the organ, tissue, cellular or molecular 
levels of biological organization. 
Methods: Pregnant female mice were administered vehicle, BPS or TBBPA during 
pregnancy and lactation. From postnatal day (PND) 19-21, two female offspring from 
each litter were administered either oil or ethinyl estradiol, and killed at PND22. One 
additional female per litter was killed at week 16. The reproductive tracts were examined 
v 
 
for gross morphological defects and then fixed and frozen for basic histological, 
immunohistological and gene-expression assessments. 
Results: Our study identified significant differences in ovarian follicular formation and 
gene expression after developmental exposures to BPS or TBBPA. Most effects were 
observed at PND22, and were apparent after an estrogen challenge; however, these 
differences were not observed at 16 weeks of age suggesting that changes induced by 
BPS and TBBPA are age dependent.  
Conclusions: Our results suggest that TBBPA and BPS alter development of the female 
reproductive tracts, with the most obvious effects on the pre-pubertal ovary after 
developmental BPS treatment. These findings are among the first to examine the effects 
of these two chemicals and indicate that widespread exposures to BPS and TBBPA may 
have implications for public health. Further, evidence regarding negative health effects 
after animal exposures to widely available EDCs may explain the global increase in 
female reproductive health abnormalities in humans. 
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CHAPTER 1 
INTRODUCTION 
1.1 Introduction to Endocrine Disrupting Chemicals 
 Today, both humans and wildlife live in an environment that contains a multitude 
of man-made chemicals which have been produced for use as pesticides, industrial 
compounds, in personal care products, fertilizers, plastics and other packaging materials, 
pharmaceuticals, and others. Unfortunately, these compounds can have unintended health 
outcomes on biota. Subsets of these chemicals are capable of mimicking or interfering 
with the actions of hormones and thus cause disturbances within the endocrine systems of 
exposed humans and animals. When disturbances to hormone signaling processes cause 
adverse health effects in the organism itself or in its offspring, they are referred to as 
endocrine disrupting chemicals (EDCs) (Bergman et al. 2013). In 2009, the Endocrine 
Society described EDCs as “compounds, either natural or synthetic, which through 
environmental or inappropriate developmental exposures alters the hormonal and 
homeostatic systems that enable the organism to communicate with and respond to its 
environment” (Diamanti-Kandarakis et al. 2009). In 2012, the Endocrine Society 
simplified this definition, describing an EDC as “an exogenous chemical, or mixture of 
chemicals, that can interfere with any aspect of hormone action” (Zoeller et al. 2012) The 
concept of “hormone action” was further described as the ability of an exogenous 
chemical to activate a hormone receptor either directly or indirectly resulting in 
physiological effects (Zoeller et al. 2014). 
 The majority of EDCs that are present in the environment are products of human 
manufacturing; however, there are also naturally occurring substances that are able to 
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disrupt endocrine pathways. These natural EDCs include metals such as arsenic, 
cadmium, lead and mercury; natural hormones such as estradiol and testosterone excreted 
from animals and humans; and phytoestrogens such as isoflavonoids and coumestans 
derived from plants (Bergman et al. 2013). Although these naturally occurring EDCs 
have potential adverse effects that should be accounted for, and in fact there are 
documented examples of these natural EDCs disrupting reproductive health, 
anthropogenic EDCs pose threats to human and wildlife health while providing important 
paths for public health interventions. This report will focus solely on anthropogenic 
EDCs.  
 The field dedicated to the study of EDCs is fairly new, and in fact the term 
‘endocrine disruptor’ was first coined in 2001 (Vandenberg et al. 2015). Up until the 
early 2000s, the majority of knowledge concerning compounds that interfere with 
hormone signaling was based on studies involving chemicals created for and used in 
industry, agriculture and pharmaceuticals. These studies focused on a very limited 
number of environmentally persistent organic pollutants (POPs) such as polychlorinated 
biphenyls (PCBs), dichlorodiphenyltrichloroethane (DDT) and polychlorinated 
dibenzofurans (PCDFs), which are reviewed in (Bergman et al. 2013). Apprehension 
within the scientific community toward these anthropogenic compounds and others did 
not begin to rise until a series of unusual phenomena relating man-made chemicals to the 
decline of human, plant and wildlife wellbeing started appearing. The earliest of these 
occurrences involved the use of synthetic chemicals such as diethylstilbestrol (DES) in 
the 1930s-1970s, PCBs from 1929-1980s and DDT produced from the 1940s through the 
present time ( Li and Macdonald 2005; Marty et al. 2011). Extensive studies surrounding 
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these chemicals, and the growing field of biomonitoring and exposure science, sparked a 
realization that the number of EDCs that one may encounter on a daily basis is 
astronomically greater than what was expected in past years, and that sources of 
exposures may vary greatly (Needham et al. 2005; Needham et al. 2008; Woodruff et al. 
2011). Within the past decade, it has been revealed that EDCs originate from a wide 
range of sources including additives in consumer goods and materials such as cosmetics 
and other personal care products, food packaging, cleaning products, plastics and 
pesticides, among others. For years, this wide range of commercially available chemicals 
was excluded from the scope of scientific and health related concern because of 
expectations that these chemicals were well tested for toxicity. Currently, although the 
criteria for characterizing compounds as EDCs differs somewhat by different groups, 
more than 1000 compounds are listed as putative EDCs in the US FDA’s Endocrine 
Disruptor Knowledgebase and on lists maintained by groups such as the Endocrine 
Disruptor Exchange (Vandenberg et al. 2013b). 
 The incidence of chronic diseases such as certain cancers, diabetes, obesity, and 
cardiovascular disease (among many others) are increasing at alarming rates and are 
collectively the leading causes of illness and death globally, surpassing communicable 
disease rates even in developing countries (Barouki et al. 2012; WHO 2011). According 
to the WHO, the expected number of annual cancer cases worldwide will increase from 
14 million in 2012 to 22 million within the next 2 decades. In many instances, factors 
such as genetics, nutrition and lifestyle are not able to fully explain these striking 
increases in chronic disease. Despite this lack of etiological explanations, research 
conducted in wildlife and laboratory animal populations point to environmental factors 
4	
	
such as chemical exposures as likely contributors to rising incidences of chronic diseases. 
It is important to recognize the burden that these diseases place on societies worldwide. 
The increasing rates of chronic disease pose concerns for public health agencies as they 
drive the need for increased medical attention and services.  Costs that accompany health 
care required to treat these diseases put drastic stress on economies; for example, it is 
estimated that global spending on diabetes alone is expected to rise to $490 US billion in 
2030, which is 12% of all health care spending (Zhang et al., 2010). Increased spending 
on health care related to chronic illness and diseases is referred to as the “global burden 
of disease” and is among the current leading public health concerns globally. 
 There are a few key factors that designate EDCs as environmental health 
concerns. First, as stated above, EDCs have the ability to interact with normal hormonal 
processes and functions within an organism, potentially causing disturbances in major 
physiological systems such as development and reproduction, resulting in adverse health 
effects. Second, although not true of every EDC, many of these compounds tend to be 
lipophilic molecules, and thus are efficiently stored in fat deposits and fluids of the body 
at a faster rate than they are excreted, a process known as bioaccumulation. In pregnant 
females, these lipophilic substances can be passed to neonates by crossing the placental 
barrier, thus exposing the fetus to a variety of concentrations and mixtures of potentially 
hazardous components (Barr et al. 2007). Lastly, many EDCs and/or their byproducts 
have the ability to accumulate with increasing order within the food chain, a process 
known as biomagnification, which allows these chemicals to accumulate in adipose tissue 
of living organisms and persist long after the chemical was first released into the 
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environment. This process produces the most risk to organisms at the top of the food 
chain such as humans and other high-order carnivorous species.  
  
1.2 Bisphenol S and Tetrabromobisphenol A 
Bisphenol S (BPS) is a chemical that is structurally similar to Bisphenol A (BPA) (Figure 
1), a known EDC that has been shown to induce adverse effects at low doses, especially 
in reproduction and developmental outcomes (Richter et al. 2007; Rochester 2013; 
Vandenberg et al. 2010; Vandenberg et al. 2013a). BPA is predominantly used in the 
production of polycarbonate plastics, both of industrial and consumer grade; thermal 
papers commonly used for receipt paper; epoxy linings of food and drink containers; as 
well as other various consumer and industrial products including toys, medical 
equipment, and sports safety equipment, among others (Geens et al. 2012; Huang et al. 
2012). Human exposure to BPA occurs predominantly by two routes of exposure: 
absorption through the skin or by ingestion; inhalation may also be possible as BPA is 
found in air and dust samples (Vandenberg et al. 2013a). BPA is an extremely lipophilic 
molecule allowing it to be absorbed through the skin by mere contact with items 
containing BPA, such as thermal receipt paper (Biedermann et al. 2010; Zalko et al. 
2011). Additionally, BPA leaches out of food and drink packaging and enters the body 
via ingestion (Vandenberg et al. 2007).  
Over the past decade, public knowledge regarding adverse outcomes related to 
BPA exposure has increased, resulting in consumers’ unwillingness to buy products 
containing this compound. To appease consumer concerns, industries such as the largest 
thermal receipt paper supplier in the US have begun to replace BPA with other related 
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chemical, such as thermal receipt paper (Porras et al. 2014).  BPS also leaches out of food 
and drink packaging and enters the body via ingestion (Bittner et al. 2014; Ozaki et al. 
2004) and is also present in dust, which can ultimately enter the body through ingestion 
(Liao et al. 2012b).  
As discussed elsewhere (Vandenberg et al. 2015), the introduction of BPS to the 
consumer market as a replacement of BPA may be an example of a regrettable 
replacement, where one compound is phased out and another with toxicity is used in its 
place. If BPS does have endocrine disrupting properties, this would be an emerging 
public health concern as approximately 81% of humans have traceable levels of BPS 
metabolites in their urine; Japan and the US have the highest BPS detection frequencies 
which may be attributed to the replacement of BPA with BPS in these two countries 
(Liao et al. 2012a).         
 Tetrabromobisphenol A (TBBPA) is also a chemical derivative of BPA created by 
brominating BPA in an organic solvent (Figure 1). TBBPA is used as a reactive flame 
retardant that is chemically bound to epoxy and polycarbonate resins used in the 
manufacturing of electronic circuit boards and textile adhesives, and is used worldwide 
(Alaee et al. 2003). The purpose of flame retardants is to decrease a product’s chance of 
igniting. Because this compound is released or shed from many consumer products, 
TBBPA is present in indoor air, dust and river sediment; it enters the body through oral 
ingestion via dust particles or from contaminated food or water (Butte and Heinzow 
2002; Oberg et al. 2002).    
There are two main concerns regarding TBBPA and its effects on health. The first 
concern is that TBBPA, like BPS, is structurally similar to BPA; as structure is often 
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predictive of biological action, it has been hypothesized that it has the potential to act as 
an EDC. The second concern is that TBBPA is persistent in the environment due to its 
bromine groups which allows TBBPA to bioaccumulate within the body including blood 
and adipose tissue (Jakobsson et al. 2002; Shen et al. 2012; Thomsen et al. 2001). One 
study observed biomagnification of TBBPA up through wild herring gull food chains and 
also detected TBBPA in herring gull eggs, consistent with the substance’s persistence in 
the environment (Letcher and Chu 2010). A human study of French mothers found 
concentrations of TBBPA ranging from 0.062 to 37 ng/g fat in breast milk (Cariou et al. 
2008). More recently, TBBPA was found in breast milk of a cohort of Japanese women at 
concentrations of 0.14 to 8.7ng/g lipid (Nakao et al. 2015). These examples emphasize 
that exposures to TBBPA can occur in developing young in both wildlife and human 
populations. Similar to BPS, controlled exposure assessments regarding TBBPA and 
resulting health outcomes remain largely unstudied. 
 Despite meager data available that examines adverse health effects induced by 
BPS and TBBPA, some recent studies suggest that these two compounds have endocrine 
disrupting properties.  Molina-Molina et al. observed that BPS and TBBPA are able to 
disrupt multiple nuclear receptors in vitro and therefore may have the ability to interfere 
with the endocrine system (Molina-Molina et al. 2013). BPS was found to be an agonist 
for both estrogen receptor  (ER) and estrogen receptor  (ER) and TBBPA was 
found to be a weak agonist for human pregnane X receptor (PXR). This study also 
revealed that BPS but not TBBPA was able to stimulate cell proliferation in MCF-7 cells 
and inhibit proliferation of MCF-7 AR1 cells. These findings suggest that BPS has 
estrogenic and androgenic properties and is able to induce estrogen and androgen 
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dependent outcomes, whereas TBBPA is able to induce xenobiotic detoxification through 
binding with PXR. However, this study did not observe estrogen regulation effects 
associated with TBBPA exposure. In contrary, Olsen and colleagues found that TBBPA 
was able to bind to estrogen receptor isolated from MCF-7 cells, increase levels of 
estrogen-regulated proteins and induce progesterone receptor (Olsen et al. 2003). Finally, 
although studies of BPS in mammals are limited, studies in zebrafish support the 
hypothesis that this chemical can disrupt both reproductive and developmental endpoints 
(Ji et al. 2013; Kinch et al. 2015; Naderi et al. 2014). 
 
1.2.1 Regulation of BPS and TBBPA 
 In 1995, the United Nations Environment Programme (UNEP) called for a global 
recognition and action against further production of persistent chemicals.  In 2001, an 
international environmental treaty known as “The Stockholm Convention” composed 
guidelines for a select group of chemicals, coined POPs (persistent organic pollutants), 
which are known to be highly persistent and are capable of long distance transport in the 
environment. These guidelines set a plan to regulate, reduce and/or completely 
discontinue the use and production of these compounds.  In theory, the Stockholm 
Convention would apply to TBBPA however; TBBPA is not currently listed as a POP in 
the Stockholm Convention. In fact, TBBPA is the primary flame retardant used 
worldwide, accounting for 58.7% of total brominated flame retardant use.  
 The use of BPS in consumer products is currently increasing due to restrictions 
put in place by the US Environmental Protection Agency (USEPA), Health Canada, and 
the European Food Safety Authority (EFSA) that limit the use of BPA in consumer 
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products (Kinch et al. 2015). Heightened consumer knowledge and concern regarding the 
use of BPA in consumer products also drives product manufacturers to replace BPA with 
BPS in order to produce “BPA-free” items, thus ameliorating consumer demand for 
“safer” alternatives. Currently, no US government agency tests for toxicity of new 
materials before they are used in consumer products and released to the public (Kinch et 
al. 2015).  
 The use of TBBPA and BPS in consumer products is largely unregulated 
worldwide. Due to the lack of control regarding the use of these chemicals, items 
containing BPS and TBBPA continue to be available to consumers, leading to 
widespread human exposures to these two environmental toxicants. 
 
1.3 The issue of risk assessment  
 The risk assessment process involves four steps: first, hazard identification 
requires that the biological/toxicological effects of a compound are assessed, typically 
using standard protocols. Next, dose response assessments are performed, allowing for 
the prediction of specific hazards at specific doses, as well as the prediction of hazards at 
doses that were not tested. In the third step, exposure assessments are conducted; this 
process allows for the identification of sources and routes of exposure. Finally, the data 
from these first three steps is combined in a risk characterization process, and the risk to 
the population is estimated.  
Risk assessment is often criticized as a non-scientific process, particularly 
because of studies showing that risk assessment decisions rely on ‘expert judgment’ and 
are often not reproducible (Frumkin 2005). Risk assessments for EDCs have also been 
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challenged, although the issues that influence assessments for this class of compounds 
differ somewhat from the concerns that have been raised regarding risk assessments in 
general. These matters are discussed in some depth below.  
 First, traditional risk assessments operate under the assumption that all chemicals 
act through a linear dose-response mechanism. This theory encompasses an expectation 
of increasing response for a set endpoint with increasing concentration of chemical in a 
linear fashion. Under this assumption, not only are higher doses expected to induce 
greater effects, there is an assumption that the effects at lower doses can be predicted 
based on high dose studies.  Importantly, this “one model fits all” ideology should be 
applied to all types of chemicals when assessing associated risks. It has been shown that 
natural hormones as well as EDCs can defy the expectation of linear or monotonic dose 
response curves, and instead can include more complicated, non-linear dose responses 
including non-monotonic dose responses curves (NMDRCs). The term NMDRC simply 
means that the slope of the dose response curve changes from positive to negative or visa 
versa at some point of change in dose, usually resulting in a U-shaped or inverted U-
shaped dose-response curve. This topic has been reviewed in detail by Vandenberg and 
colleagues (Vandenberg et al. 2012).    
 Hormones act via high-affinity binding to specific proteins known as receptors. 
Downstream effects of hormones are induced when a hormone successfully binds to a 
receptor and activates a cascade of cellular events including gene transcription. Hormone 
receptors are limited and present only in specific cells and tissues within an organism. If 
receptors are not present, hormones will not have the ability to act or induce a response.  
Considering these hormone-receptor interactions, there are a number of mechanisms that 
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have been characterized, largely by endocrinologists, to explain how hormones and EDCs 
can induce NMDRCs. One mechanism is explained by the non-linear relationship 
between hormone concentration, number of bound receptors, and biological effects 
(Welshons et al. 2003). Due to limited number of hormone receptors, receptors become 
saturated when hormone concentrations are high. In this case, response is not solely 
dependent upon the concentration of hormone but also dependent upon the number of 
bound receptors as response is dictated by the number of bound hormone-receptor 
complexes; the greater the number of bound hormone-receptor complexes, the greater the 
magnitude of response.  
 Other factors that can contribute to the manifestation of a NMDRC have also been 
described. The first of these factors is the possibility of receptor down-regulation in the 
presence of a high concentration of hormone. At high hormone concentration, the rate of 
receptors lost (due to movement of bound receptors to other sites within the cell such as 
the nucleus) is greater than the rate of receptor replenishment, resulting in a response-
limiting factor.  Another factor that contributes to NMDRCs is the ability of some 
hormones to bind to multiple different types of receptors; this affinity to different 
receptors is typically based on the concentration of hormone. In this case, at low 
concentrations the hormone may only bind to receptors that have a very high affinity for 
that particular hormone whereas at high hormone concentrations the hormone may also 
bind to receptors that have a lower affinity for that particular hormone; the resulting 
observed response is due to the hormone binding with multiple classes of receptors.  
Endogenous estrogens and xenoestrogens both follow this receptor affinity factor 
and can produce NMDRCs. An example of this factor is illustrated by the response of 
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estrogen dependent breast cancer cells that are treated with Tamoxifen, resulting in what 
is known as “Tamoxifen flare”. At low doses of Tamoxifen, breast cancer cells 
proliferate, but as concentrations increase in the blood, the “therapeutic range” is 
achieved, and cancer cells stop proliferating. At higher doses, apoptosis is induced in 
these cancer cells, and at even higher concentrations, Tamoxifen induces systemic 
toxicity. In this example, the least toxicity is observed at a moderate dose of the drug 
(Reddel and Sutherland 1984).  
 Another related issue that has challenged traditional risk assessment methods is 
the ability of EDCs to induce adverse effects even when exposures occur at low doses or 
concentrations. Although the term “low dose” has many different definitions, the 
National Toxicology Program (NTP) defines low dose effects as “ any biological changes 
1) occurring in the range of typical human exposures or 2) occurring at doses lower than 
those typically used in standard testing protocols” (Melnick et al. 2002). As mentioned 
above, a biological response can occur only when a hormone successfully binds to its 
receptor. Low dose effects are possible because receptors are rarely if ever saturated, 
meaning that even low concentration of hormone or EDC can increase the number of 
receptors bound, resulting in maximal response even at a low dose.   
 Finally, the method used to assess the effects of EDCs have been challenged, with 
some suggesting that the endpoints examined in traditional guideline studies are not 
relevant to human diseases of concern (Myers et al. 2009a; Myers et al. 2009b). In risk 
assessments, EDCs are typically treated the same as every other chemical, i.e. assumed to 
have general toxicity, and assessed based on the linear response model. If chemicals that 
act as hormone receptor agonists are only tested at doses where a traditional toxic 
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response (i.e. death, loss of body weight) is expected based on the linear response model, 
entire responses are left unassessed at lower doses. Unfortunately, this reliance on an 
expectation of a monotonic dose response may leave entire groups of chemicals such as 
potential EDCs inadequately assessed. 
 
1.4 The ovary 
 The ovaries are essential female organs that carry out crucial roles in both the 
endocrine and reproductive systems. The ovaries house germ cells and also generate and 
release multiple steroidal and non-steroidal hormones directly into the blood stream; 
these hormones play important roles in endocrine feedback systems. Mammalian females 
possess a maximum number of germ cells or oocytes at birth. Their numbers continually 
decrease after birth until all oocytes have been ovulated or have died via various 
apoptotic pathways; when all oocytes have been expended, the female enters a period 
known as menopause. Human females are born with approximately 2 million primordial 
oocytes; by the time puberty is reached, only about 400,000 remain (Kovacs and Ojeda 
2011). The number of primordial oocytes present in mouse ovaries is highly debatable 
because follicle counting methods involve a great amount of error and numbers vary 
greatly depending on the strain of animal and methods used (Tilly 2003). The total 
estimated number of follicles in the mouse ovary reported varies from 3,500 to 30,000 
(Pepling and Spradling 2001). 
 
1.4.1 Follicle development 
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 At birth, the oocytes present in the ovary are known as primary oocytes. These 
primary oocytes undergo stages of follicle maturation based on changes in concentration 
of gonadotropins, luteinizing hormone (LH) and follicular stimulating hormone (FSH), 
which are released from the anterior pituitary. Ovulation in humans is regulated by a 
cyclic mechanism known as the menstrual cycle; one oocyte is ovulated approximately 
every 29.5 days. Ovulation in the mouse follows a different pattern known as the estrus 
cycle; environmental cues such as amount of light signal ovulation of multiple oocytes 
(Gilbert 2010a). The first phase of follicle development is categorized by a series of 
developmental maturation steps where follicles can be categorized as follows: 1) 
Primordial follicles include primary oocytes surrounded by a flat layer of epithelial cells. 
2) Primary follicles contain the oocyte and a single or double layer of granulosa cells that 
are formed from the epithelial cells. Granulosa cells have FSH receptors and their main 
function is to convert androgens to estradiol. 3) Secondary follicles contain the oocyte 
surrounded by more than two layers of granulosa cells and an outer layer of theca cells 
that are derived from stromal cells. Theca cells have LH receptors and produce 
androstenedione, which is used by granulosa cells to convert androgens to estradiol. 4) 
Antral (or graafian) follicles contain the oocyte surrounded by two or more layers of 
granulosa cells, outer theca cell layers and contain a large follicular fluid filled 
compartment known as the antrum (with a high concentration of steroids and local 
growth factors).  
After follicular maturation is complete, the second stage of the follicular phase 
begins. In this second phase, mature follicles become dominant and each mature follicle 
expels its ovum into the fallopian tube where it can be fertilized in a process known as 
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development in a mouse ovary. An image showing the histological appearance of a 
corpus luteum is also shown. 
 
1.4.2 Development of the ovary/oogenesis  
The ovary and the female germ-line undergo development during prenatal and postnatal 
development, and are marked by two rounds of meiosis. In mice, primordial germ-cells 
migrate to the ovaries at approximately days 7-11 of gestation, and germ-cell meiosis I 
begins at gestational day 13, when germ-cells begin to proliferate and develop into 
primordial follicles and follicles (Borum 1961; Smith et al. 2014). Primordial germ-cells 
assemble within the ovary into what is referred to as the “follicle reserve” or “oocyte 
nest” (Kerr et al. 2013; Uzumcu et al. 2012). In humans, the process of primordial follicle 
assembly occurs during gestation and is complete by birth whereas in rodents, primordial 
follicle reserves do not completely form until postnatal day 2-3 (Kerr et al. 2013). These 
reserves contain a finite number of primordial follicles that will either mature through the 
stages of follicular development (discussed in Section 1.4.1) and ovulate or will die 
throughout an individuals’ lifespan; about 99.9% of growing follicles are atretic (Uzumcu 
et al. 2012). Ultimately, the number of viable primordial follicles present at or near birth 
dictates the length of the reproductive life span. These primordial follicles remain 
inactive in meiotic arrest of the diplotene stage of prophase I until puberty, when groups 
of primordial follicles begin follicular growth. At puberty, LH surges from the pituitary 
will signal select primordial follicles to continue and complete meiosis I. When the 
follicles mature into a secondary follicle, meiosis II begins but halts at metaphase. 
Further continuation of meiosis II can only be completed if fertilization occurs. In the 
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human, some oocytes remain in meiotic prophase arrest for nearly 50 years (Gilbert 
2010b). 
 
1.4.3 Ovarian steroid hormones 
 There are three key families of hormones that are essential for the control and 
maintenance of ovarian maturation as well as endocrine feedback loops that involve the 
ovary.  These families include estrogens, androgens and progestins. The primary estrogen 
secreted by the ovary is 17β-estradiol (E2). In the ovary, E2 primarily acts via binding to  
estrogen receptor (ER)-, which is present in granulosa cells. E2 induces proliferation and 
decreases apoptosis of granulosa cells, as well as maintains FSH responsiveness and 
creates LH receptors. Testosterone is the primary androgen that participates in ovarian 
feedback loops. Testosterone binds to androgen receptors (AR), which are present in 
granulosa cells and increases E2 and progesterone secretion through FSH stimulation. 
Progesterone is the major hormone in the progestin family. Like AR and ER, 
progesterone receptors (PR) are expressed in granulosa cells. Progesterone, known as the 
“pregnancy hormone”, inhibits E2 production that is induced by FSH (Kovacs and Ojeda 
2011). These three classes of hormones are responsible for follicular development 
(discussed above) as well as for providing input needed to control other endocrine 
hormones outside of the ovary.  
 
1.4.4 The hypothalamic-pituitary-ovarian (HPO) axis 
 Female reproductive hormones are regulated by a system of endocrine organs 
including the hypothalamus, the anterior pituitary gland, and the ovaries, known as the 
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 E2 acts directly on both the hypothalamus and the anterior pituitary to inhibit 
hormone secretion. E2 secreted from the ovaries inhibits secretion of gonadotropin 
releasing hormone (GnRH) from the hypothalamus by binding to ER, thus suppressing 
GnRH neurons in the arcuate nucleus. E2 also acts on the anterior pituitary by suppressing 
gene expression of the LH -subunit, which inhibits the release of LH. Inhibition of 
hormone synthesis by the hypothalamus and pituitary decreases circulating 
concentrations of GnRH and LH, resulting in decreased production of E2, which is 
typically derived from androstenedione by thecal cells of the ovary (Kovacs and Ojeda 
2011). Inhibition of GnRH, LH and E2 via this system completes the negative feedback 
loop, which can be carried out within minutes.   
 Positive feedback of the HPO axis is also controlled predominantly by ovarian E2 
but occurs only during the follicular development phase of the menstrual or estrous cycle. 
As follicles mature, they produce more E2, which stimulates increased GnRH release 
from the hypothalamus and increased FSH and LH release from the anterior pituitary. 
Positive feedback continues throughout the follicular phase, building increasing 
concentrations of E2, FSH and LH until an LH surge, which is responsible for ovulation, 
occurs. Promptly after ovulation, positive feedback ceases as E2 secretion is inhibited by 
progesterone that is secreted by the corpus luteum.  If pregnancy fails to occur, positive 
feedback of the HPO axis will resume when the luteal phase is completed. Contrary to the 
rapid response of the HPO axis’ negative feedback system, a delay lasting several hours 
occurs before E2 is able to induce the positive feedback system (Kovacs and Ojeda 2011). 
 
1.4.5 Diseases of the ovary 
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 A few ovarian diseases are responsible for the majority of ovarian dysfunction 
including polycystic ovary syndrome (PCOS), ovarian cancer, ovarian cysts and 
premature ovarian failure. Of these ovarian complications, PCOS is the most abundant 
endocrine related abnormality in women of reproductive age, affecting up to 18% of the 
female population (March et al. 2010). The etiology of PCOS is unknown, however those 
diagnosed with PCOS have increased prevalence of insulin resistance and obesity, which 
further increases risk of developing type II diabetes and cardiovascular disease (Shaw et 
al. 2008). Due to a multitude of phenotypes associated with PCOS including 
oligomenorrhoea/amenorrhoea, clinical or biochemical hyperandrogenism and polycystic 
ovaries detected by ultrasound, debate surrounds PCOS diagnostic criteria (Azziz et al. 
2009). In addition to the increased risk of developing chronic diseases, PCOS is also 
responsible for reproductive dysfunction. The majority of women with PCOS (70-80%) 
experience oligomenorrhoea, infrequent menstruation; or amenorrhoea, absence of 
menstruation (Brassard et al. 2008). PCOS is the leading cause of annovulatory infertility 
striking up to 95% of women with annovulation (Teede et al. 2010). PCOS disrupts the 
HPO axis by increasing production and secretion of ovarian androgens, which impairs 
ovarian follicle development; excessive androgens induce other undesirable outcomes 
including excessive hair growth (Teede et al. 2010). Ovarian cysts can occur either as a 
result or independently from PCOS diagnosis. Ovarian cysts are fluid filled sacs found 
either in or on the surface of the ovary that can cause abdominal pain but often times are 
not related to any symptoms or negative health effects (Conway et al. 2014). Increased 
research and understanding of PCOS is needed to improve diagnostic and treatment 
implications. For example, because global increases in obesity rates are tightly related to 
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increasing PCOS rates, PCOS is a complicated public health issue resulting in an 
abundance of adverse health and reproductive outcomes (Shaw et al. 2008).   
 According to the American Cancer Society, ovarian cancer accounts for the most 
number of deaths out of all cancers of the female reproductive system. It is estimated that 
in 2015, more than 20,000 women will be diagnosed with ovarian cancer (American 
Cancer Society 2014). Like PCOS, the etiology of ovarian cancer is unknown; very few 
cases can be linked to genetic heredity leaving the majority of ovarian cancer cases 
sporadic (Doufekas and Olaitan 2014). Although epidemiological studies have revealed 
risk factors such as: age, genetic mutations in the BRCA1 and BRCA2 genes, previous 
endometriosis or breast cancer diagnosis, lack of parity, and others, these factors cannot 
fully explain the incidence of ovarian cancer observed  today (Doufekas and Olaitan 
2014). It is known that certain DNA or gene mutations can induce the growth of 
cancerous cells. The majority of the genetic mutations associated with ovarian cancer are 
not inherited but rather acquired throughout a woman’s life. Genetic mutations can result 
from environmental exposures to radiation or carcinogenic chemicals;  importantly, 
specific chemicals present in the environment have not yet been linked to mutations that 
result in ovarian cancer (American Cancer Society 2014).  
 Premature ovarian failure (POF) is defined as premature amenorrhea with 
elevated gonadotrophin levels observed under the age of 40; POF is commonly referred 
to as ‘premature menopause’ (Haller-Kikkatalo et al. 2015). Like PCOS, the cause of 
POF is unknown and many factors contribute to the diagnosis of this disease. Yet, 
diagnostic criteria vary and can involve assessments using ultrasound, bone mineral 
density, and serum E2 and FSH levels (Conway et al. 1996). Given the heterogeneity of 
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POF diagnostic methods, it is extremely difficult to study its prevalence; therefore 
estimates of POF prevalence vary greatly and are thought to be inaccurate (Haller-
Kikkatalo et al. 2015). POF contributes to female infertility, decreased circulating ovarian 
hormones, and increased risk of developing osteoporosis and heart disease (Lokkegaard 
et al. 2006). 
 
1.4.6 Evidence of ovarian disruption linked to EDCs 
 Although limited, controlled animal and epidemiological data are available that 
suggest adverse female reproductive effects as a result of EDC exposure. One study 
found that female rats exposed to three different doses of BPA (0.25-0.62mg/kg, 2.5-6.2 
mg/kg or 25.0-62.5 mg/kg) subcutaneously from postnatal day 1 to postnatal day 10 
experienced hormonal and reproductive changes that manifested at 4-5 months of age. 
Rats exposed to the two highest doses had significantly increased testosterone and E2 
serum concentrations, which altered GnRH secretion in the hypothalamus; furthermore, 
all treatment groups had significantly decreased progesterone serum concentrations 
(Fernández et al. 2010). Animals treated with 25.0-62.5 mg/kg BPA had large numbers of 
ovarian cysts, cystic follicles and decreased numbers of total ovarian structures. These 
animals were also unable to ovulate or produce pups; animals treated with 2.5-6.2 mg/kg 
had significantly smaller litters when mated, consistent with decreased ovulatory 
responses at this dose as well. Collectively, these results suggest that administration of 
BPA at relatively high doses during neonatal development can result in symptoms 
consistent with PCOS and cause disruption of the HPO axis.  
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 Another study observed disruption in follicular formation in rhesus monkeys 
exposed orally to 400 μg BPA/kg body weight/day late in the third trimester of fetal 
development when follicle formation occurs. This dose was demonstrated to produce 
peak serum levels of 2–5 ng/mL BPA, which is in the range of what has been reported in 
humans (Hunt et al. 2012). Animals treated daily with BPA had significantly increased 
numbers of multioocyte follicles (MOFs) and disrupted synaptic recombination between 
homologous chromosomes during meiosis. A large range of estrogenic exposures can 
induce MOFs (reviewed by (Pepling 2012)), and similar results showing MOFs induced 
by EDC exposures have been reported in mouse studies as well (Suzuki et al. 2002; 
Zhang et al. 2012). It is unclear how MOFs occur, however it is hypothesized that a delay 
in meiotic progression results in follicles that form before they undergo meiotic arrest and 
therefore are not ready for enclosure, allowing for the inclusion of multiple immature 
oocytes into one follicle. Reproductive outcomes as a result of MOFs are also unknown; 
follicular growth failure is suspected (Hunt et al. 2012).  
 Several epidemiological studies have associated EDC exposures with increased 
incidence of ovarian diseases. One study found that women diagnosed with PCOS had 
significantly higher serum BPA concentrations than similar women without PCOS (cases 
and controls, respectively) (Takeuchi et al. 2004). It was also observed that increasing 
serum androgen levels correlated with increasing serum BPA levels, suggesting that BPA 
concentration in blood is associated with a hyperandrogenic environment. Although the 
relationship between androgen and BPA concentrations in the blood is unclear, it is 
hypothesized that BPA is able to displace endogenous sex hormones from sex hormone 
binding globulin (SHBG) sites since it is a known SHBG ligand; this would lead to a 
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disruption in the androgen-to-estrogen ratio (Déchaud et al. 1999; Takeuchi et al. 2004).  
Similar results showing associations between increased BPA and androgen serum 
concentrations were found in another population of women diagnosed with PCOS 
(Kandaraki et al. 2010). It has been reported that BPA metabolism and excretion is down 
regulated by androgens through uridine diphosphate-glucuronosyl transferase activity in 
the liver (Takeuchi et al. 2006), providing further evidence for a complicated relationship 
between BPA and androgens.  
Multiple human studies have observed adverse female reproductive health effects 
associated with exposure to other EDCs including PCBs, phthalates, and hormonally 
active pesticides (reviewed by (Mendola et al. 2008)). In short, these studies have found 
associations between EDC exposures and decreased age of menarche and puberty in girls, 
irregular menstrual cycles, irregular concentrations of circulating sex steroid hormones 
and adverse pregnancy outcomes (Mendola et al. 2008). 
 In addition to the cases discussed above, Peretz and colleagues reviewed all 
studies published between 2007-2013 that examined the impact of BPA on the male and 
female reproductive systems (Peretz et al. 2014). In summary, studies using various 
animal and cellular models as well as human data observed disturbances of the ovary in 
three categories: 1) oogenesis and ovarian follicle formation; 2) steroidogenesis in 
females; and 3) the quantity, quality and fertilization capacity of oocytes. Major findings 
from these three categories include: 1) Low dose BPA exposure decreased the number of 
primordial follicles in a dose-dependent manner in mice, induced changes in gene 
expression in germ cells in mice and disrupted meiosis in mice and macaques (Hunt et al. 
2012; Lawson et al. 2011; Zhang et al. 2012). 2) Similar to the findings of Fernandez and 
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colleges, postnatal BPA exposure increased E2, testosterone and progesterone levels in 
mouse serum (Fernández et al. 2010; Tan et al. 2013). 3) Human studies reveal 
correlations between serum BPA concentrations and oocyte maturation as well as 
decreased developmental potential of oocytes (Fujimoto et al. 2011). Increasing urinary 
BPA concentrations are also correlated with decreased number of mature oocytes and 
fertilized oocytes (Mok‐Lin et al. 2010). Collectively these studies provide significant 
evidence that BPA exposure disrupts reproductive fitness of the ovary in laboratory 
animals, and similar relationships may be present in exposed humans.  
 
1.5 Developmental Origins of Health and Disease (DOHaD)  
 The “developmental origins of health and disease” (DOHaD) hypothesis, also 
known as the Barker hypothesis, recognizes that exposure to environmental stressors 
during specific windows of development can result in permanent adverse health 
outcomes, often in the form of non-communicable diseases, later in life (Barker 1995; 
Barouki et al. 2012). The association between inadequacies during fetal life and later 
onset of disease was proposed by David Barker, who in the 1980s discovered increased 
risk of cardiovascular and metabolic diseases due to insufficient nutrition during 
development as a result of the Dutch famine (Barker 2007). Developmental plasticity 
allows organisms to adapt and respond to their surrounding environment in order to 
improve survival and reproductive capability (Barouki et al. 2012). Differentiation and 
development of cells and tissues occurs during time frames of development that are 
specific to the particular organ or tissue that is being formed. Exposure to a variety of 
environmental factors including drugs, inadequate nutrition, stress, environmental 
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chemicals and other environmental factors during “critical windows of development” can 
alter cellular and epigenetic programming of specific tissues and organs including the 
ovary (Heijmans et al. 2009; Heindel and Vandenberg 2015).   
 Many chemicals are able to cross the placental barrier and enter the fetal 
circulation and/or the surrounding fetal environment including the amniotic fluid; 
therefore the developing organism can experience exposure to these compounds in utero 
(Arbuckle 2010; Woodruff et al. 2011). Furthermore, as mentioned previously, many 
environmental chemicals are highly lipophilic molecules that can bioaccumulate within 
adipose tissue and can be transferred to developing offspring through breast milk, 
resulting in exposure during critical postnatal periods of development. Persistent 
environmental chemicals found in breast milk globally have been reviewed in depth by 
several reports (Fürst 2006; Solomon and Weiss 2002). A recent study revealed that at 
least 100 chemicals are present in the cord blood of infants, which suggests that fetal 
exposure to an array of environmental chemicals including EDCs occurs during fetal 
development (Unuvar and Buyukgebiz 2012). Many studies have been performed which 
link developmental exposure to various EDCs to adverse female reproductive health 
outcomes (reviewed by (Crain et al. 2008)). The DOHaD hypothesis has been applied to 
explain the associations between developmental exposures to EDCs and increasing rates 
of reproductive diseases and dysfunctions including subfecundity, PCOS, uterine 
fibromyoma and some types of reproductive cancers (Barouki et al. 2012).  
 The DOHaD concept has become a well-recognized framework for modeling how 
environmental chemicals and other environmental factors could contribute to the 
increasing rates of chronic disease that the world’s human populations are experiencing 
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including type II diabetes, obesity, cardiovascular disease and various types of cancer 
(Barouki et al. 2012). Currently, non-communicable diseases are the most prominent 
causes of death in industrialized countries, making the study of environmental chemicals 
an important public health issue. Importantly, the DOHaD hypothesis provides new 
strategies and implications to improve research and disease prevention measures by 
creating a focus on the timing of disease (Barouki et al. 2012; Heindel and Vandenberg 
2015); if DOHaD is sufficient to explain the associations between environmental 
chemicals and later life diseases, limiting exposures to environmental toxins during 
pregnancy and childhood could prevent chronic diseases in adulthood thus, decreasing 
the global burden of non-communicable diseases. 
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CHAPTER 2 
PROJECT RATIONALE 
 
 Throughout the past several decades an overwhelming amount of scientific data 
has been published regarding EDC exposures and related negative health outcomes. 
EDCs differ greatly from other classes of environmental chemicals, posing complex 
questions regarding the understanding of biological and physiological actions and effects 
of EDCs, and creating debate in the scientific community. Current risk assessment 
methods assess chemicals as if they follow a classic linear dose-response model, 
assuming that low doses are less harmful than higher doses. At least some of the time, 
EDCs defy this expectation; diverse adverse health effects are often induced at low doses.  
BPS and TBBPA are ubiquitous in the environment and are structurally similar to 
the EDC BPA, which has an array of known negative health outcomes associated with its 
exposure. The use of these chemicals is largely unregulated and human populations 
globally are exposed on a daily basis. The public health and environmental concern at 
hand is the potential of negative health effects to arise due to BPS and TBBPA exposure. 
When looking at this issue from a DOHaD lens, this issue is especially concerning to 
pregnant women and children who face exposure during critical developmental windows. 
 In this report, I analyze the results observed from exposing mice perinatally to 
BPS and TBBPA by looking at developmental endpoints relevant to ovarian development 
and a small number of additional estrogen-sensitive endpoints. The chemicals BPS and 
TBBPA are hypothesized to act as EDCs based on previous exposure reports and their 
similarity in structure to BPA, a well-studied EDC; this is the major rationale for the 
selection of BPS and TBBPA for this study.  
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The ovary was chosen as the organ of study for two main reasons: 1) The ovary is 
an organ that is highly sensitive to hormones and EDCs therefore, if hormonal disruption 
is taking place, we would expect to see changes within the ovary. 2) The ovary is 
involved in the complex HPO axis, which provides strict control of multiple hormones 
via positive and negative feedback systems. If hormone disruption occurs at any of the 
three organs involved in the HPO axis (hypothalamus, pituitary, ovaries), we would 
expect to see changes in the ovary. Observed endpoints were carefully selected in order 
to observe potential changes in the ovary at a gross, cellular and molecular level. Gross 
alterations were assessed during necropsy by looking for abnormalities such as ovarian 
cysts and measuring uterine weight. Changes at the cellular level were assessed through 
histological analysis of ovarian sections. Finally, immunohistochemistry and qPCR 
provided data regarding changes in the ovary at a molecular level via protein and gene 
expression analysis.   
 
2.1 Hypothesis Statement 
 Based on previous studies that link developmental exposure to similarly 
structured environmental EDCs to adverse female reproductive outcomes, I hypothesize 
that developmental exposure to BPS and TBBPA will induce changes in estrogen 
dependent endpoints such as ovarian development, with effects observed on a cellular 
and molecular level. This supports an additional hypothesis that BPS and TBBPA are 
capable of disturbing ovarian hormone functions via estrogen dependent pathways and 
should be considered EDCs. 
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CHAPER 3 
METHODS AND MATERIALS 
3.1 Animals 
 Adult outbred CD-1 mice of both sexes were obtained from Charles River 
Breeding Laboratories (Raleigh, NC). The CD-1 strain has previously been shown to be a 
sensitive model for the use of reproductive endocrine disruption studies (Peretz et al. 
2013). All procedures with mice were reviewed and approved by the Institutional Animal 
Care and Use Committee at the University of Massachusetts, Amherst. Two females and 
one male were housed together in a ventilated cage until pregnancy was confirmed via 
the presence of a vaginal plug. Pregnant females were housed with up to two other 
females of the same dosing group until pregnancy day 17. On pregnancy day 18, each 
pregnant female was separated into her own cage in preparation for delivery. A 0600–
1800 hours light cycle and a controlled temperature of 25–27 °C was followed for the 
entirety of the experiment.  Standard rodent chow and water were provided for ad libitum 
consumption. 
 
3.2 Chemical administration 
 Females were randomly assigned to exposure groups using statistical methods to 
ensure similar body weights across treatment groups. Females were ear-tagged upon 
arrival to allow for their identification; identification tags were coded so that 
experimenters were blind to treatment throughout the experiment.  
 The day that a vaginal plug was observed was considered embryonic day 1 (E1). 
Pregnant females were orally dosed with 200g/kg of body weight/day of BPS in corn oil 
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3.3 Tissue and body weight collection 
 Only female pups were used in this experiment. As mentioned above, two female 
pups from each litter were sacrificed on PND22 (one treated with ethinyl estradiol, and 
one treated with corn oil, from PND19-PND21). From these females, ovarian and uterine 
tissues were collected; body weight was also measured at time of sacrifice. At 16 weeks 
of age, 1-2 female pups from each litter were sacrificed, ovarian and uterine tissues were 
observed for gross abnormalities, then collected as described below; uterine weight and 
body weight were also measured. The remaining female pups were sacrificed at 24 weeks 
of age, and ovarian and uterine tissues were collected and uterine weight was measured. 
Individual body weight was again recorded on the day of euthanasia. At all ages, one 
ovary and one horn of the uterus from each animal were frozen at -80°C for qPCR 
analysis. The second ovary and the remainder of the uterus were fixed in neutral buffered 
formalin for histological analysis.   
 
3.4 Behavioral assessments 
 Females were assessed in an Open Field test at three different ages: PND22-24 
(pre-puberty), 15 weeks, and 23 weeks of age. Briefly, the Open Field test involves the 
placement of females in a clear plexiglass cage sized 40 cm x 40 cm x 40 cm. Females 
were observed for 5 minute periods without experimenter intervention. At all three ages, 
the Noldus Ethovision software was used to record basic parameters including: distance 
traveled, average speed, and cumulative duration in the center of the apparatus. During 
the 15 week and 23 week experiments, additional data was collected by hand including 
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number of rears on walls, number of rears in the center of the open field, number of 
crosses through the center of the apparatus, and time spent grooming. 
 
3.5 Analysis of follicle formation 
 To characterize follicle formation, fixed ovaries from PND22 and week 16 
females were processed through a series of alcohols and embedded in paraffin. Paraffin 
blocks were sectioned at 5μm on a Fisher rotary microtome and mounted on positively-
charged glass slides. Sections were processed through a series of xylene and ethanol, 
stained with hematoxylin and eosin, dehydrated, and coverslipped with permanent 
mounting medium. Images were collected on a Zeiss AxioImager Inverted Microscope 
with ZEN imaging software and a Zeiss high resolution color camera with a 20x EpiPlan 
Objective.  
 To score follicles, every tenth section throughout the entire ovary was analyzed, 
corresponding to one section per 50μm of ovary. In addition to the analysis of sections 
from the entire ovary, four consecutive sections from the medullary region were analyzed 
separately to minimize statistical error due to variation between ovarian sizes.  Sections 
were coded, allowing for scoring by a blinded observer. Follicles were scored using 
methods modified from those described previously (Hunt et al., 2012) and categorized 
into five categories depending on the stage of follicle development: primordial, primary 
1, primary 2, secondary and antral (Figure 2). Follicles were scored as: “primordial” if 
the nuclei were along the cortex of the ovary and had no granulosa cell formation; 
“primary 1” if they had one layer of granulosa cells around the nucleus; “primary 2” if 
they had two layers of granulosa cells but no theca cells around the nucleus; “secondary” 
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if they had more than two layers of granulosa cells and at least one layer of theca cells 
around the follicle; and “antral” if they had the same criteria of a secondary follicle with 
the addition of a follicular fluid-filled antrum.  Follicles of these various stages are shown 
in Figure 2. The total number of oocytes, total number of follicles, and total number of 
corpus lutea (when appropriate) were also counted for each section of ovary analyzed. 
 
3.6 Immunohistochemistry 
3.6.1 Technical methods 
 For each primary antibody of interest (Ki67, ER), one 5μm ovarian tissue 
section per female was analyzed. In total, sections were analyzed from one female per 
litter from each of the following groups: 1) at PND22 after three days’ treatment with oil; 
2) at PND22 after three days’ treatment with ethinyl estradiol; and 3) at 16 weeks of age. 
Ki67 antibodies were obtained from Vector Labs (rabbit polyclonal, Cat# VP-RM04) and 
ERα antibodies were obtained from Millipore (rabbit polyclonal, Cat# 06-935). 
Antibodies were first optimized for ovarian tissue and the optimum concentration found 
for Ki67 and ER was determined to be 1:1000.  
For immunohistochemical analysis, a protocol developed previously was 
modified.  Briefly, a series of xylene and ethanol washes was used to remove the paraffin 
from the tissue. For antigen retrieval, microwave treatment paired with citric acid buffer 
was used followed by a step for quenching endogenous peroxidase activity. Non-specific 
antibody sites were blocked using normal goat serum 1:20 in 1.5% milk. After overnight 
incubation with the primary antibody at 4°C, the tissue was incubated with the biotin 
labeled anti-rabbit secondary antibody (Abcam Cat# ab64256) for one hour at room 
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temperature, and the reaction was developed with streptavidin peroxidase complex 
(Abcam Cat# ab64269). Finally, a color-change reaction was obtained using DAB (3,3-
diaminobenzidine, Abcam Cat# ab64238) and tissue was counterstained with 
hemotoxylin before being cover-slipped with permanent mounting media.   
3.6.2 Analysis 
 Each sample was imaged with a Zeiss AxioImager Inverted Microscope with a 
20x EpiPlan Objective with ZEN imaging software and a Zeiss high-resolution color 
camera. All analyses were conducted by an observer blind to treatment. When possible, 
two of each follicle type with granulosa cells discussed above in section 3.5 (primary 1, 
primary 2, secondary, antral) were analyzed. Follicles were analyzed by counting the 
number positive/brown cells (both granulosa and theca cells were counted) and by 
counting the number of negative/blue cells (again, both granulosa and theca cells were 
counted). The total percentage of granulosa and theca cells that were positive for the 
specific antibody being tested was then calculated (# positive / total number counted x 
100). Corpus luteal cells were also analyzed (when appropriate) by counting the number 
of positive/brown and negative/blue luteal cells. Total percent positive luteal cells were 
calculated. 
 
3.7 qPCR 
3.7.1 RNA isolation from tissue 
 Ovaries collected from female mice described in Section 3.3 were homogenized 
individually in Trizol to lyse cells and release RNA. Chloroform was added to each 
sample and samples were then spun in a microcentrifuge at 4o for 15 minutes to separate 
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the RNA from Trizol and RNA was precipitated with isopropanol, washed twice with 
75% ethanol, and suspended in 50l of RNase-free water. The RNA concentration and 
purity (260/280) was determined by Nano-drop. Samples were stored at -800. 
3.7.2 cDNA synthesis 
 Reactions were performed in PCR tubes on ice using the iScript Reverse 
Transcription Supermix for RT-qPCR kit (Cat 170-884, BioRad, Hercules, CA). Three 
categories of reactions were carried out. The first category contained RNA samples that 
underwent reverse transcription to produce cDNA. This reaction utilized 1g of RNA 
from step 3.7.1 and 4g of 5x iScript RT supermix. The second category was a no reverse 
transcriptase (NRT) control, to control for genomic DNA that may have contaminated the 
sample. The NRT control contained 1g of RNA from step 3.7.1 and 4g of 5x iScript 
RT supermix no RT control. A NRT control was made for each sample of RNA. The 
third category was a no template (NT) control to control for the possible self-
amplification of primers. The NT control contained 1g of reverse transcriptase. Only 
two random NT controls were made since they were reused as controls. All samples were 
run on a BioRad thermal cycler using standard temperature and time protocols: 25o for 5 
minutes, 42o for 30 minutes, 85o for 5 minutes, 4o for . Samples were stored at -80o. 
3.7.3 Primer design 
 The UCSC genome browser (genome.ucsc.edu) for mouse (Mus musculus) was 
used to select nucleotide sequences of two sequential exons. The forward primer was 
designed to sit on a selected exon of the gene of interest and the reverse primer to sit on 
the very next exon downstream of the first selected exon. Primers were developed using 
the Primer3Plus database (http://www.bioinformatics.nl/cgi-
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bin/primer3plus/primer3plus.cgi/). The exon sequences recorded from the USCS genome 
browers were used to generate forward and reverse primers. After primers were generated 
in Primer3Plus, primer sequences were put into the UCSC BLAT search genome function 
to verify that the primer sequences were 100% specific and that they lie on the correct 
chromosome. Primer sequences are listed in Table 1 and are shown from 5’ to 3’. 
3.7.4 qPCR 
 All reactions were assembled in eppendorf tubes on ice. For each sample of RNA, 
a RT and NRT control sample were analyzed. For each qPCR run, one NT control sample 
was analyzed. First, yeast tRNA was prepared by diluting 50ug/ml stock solution to a 
1:200 dilution with dH20. Yeast tRNA was used to prevent cDNA from sticking to the 
sides of the eppendorf tube. Next, cDNA samples from 3.7.2 were diluted 1:10 into yeast 
tRNA made in the previous step. The supermix solution was then made by combining 
10l iTaq Universal SYBR Green Supermix (Cat 172-5124, BioRad) and 3l of dH20 per 
sample. The supermix solution was then evenly distributed into each of the tubes 
containing cDNA and yeast tRNA, 15l of this solution was distributed into new 
eppendorf tubes (enough tubes for each of the primers being analyzed.) The PCR reaction 
mix contained 5l of the desired primer solution from 3.7.3 (containing both forward and 
reverse primers) and 15l of the supermix solution, resulting in 20l of total solution for 
each sample. Samples were briefly vortexed and spun in a centrifuge to condense all 
liquid to the bottom of the tube. In a 384 well PCR plate, 5l of the PCR reaction mix 
was pipetted into three consecutive wells and the plate was sealed with adhesive film. 
PCR reactions were carried out with a BioRad CFX384 real time cycler using standard 
temperature and time protocols.  
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Table 1. Primer sequences used for qPCR analysis 
Gene Forward primer 
sequence 
Reverse primer sequence 
Androgen 
receptor/AR 
AAG ACC TGC CTG ATC 
TGT GG 
TCG TTT CTG CTG GCA CAT 
AG 
Epidermal growth 
factor receptor/EGFR 
TCT TCA AGG ATG TGA 
AGT GTG 
TGT ACG CTT TCG AAC AAT 
GT 
Estrogen 
Receptorα/Esr1 
TGC AAT GAC TAT GCC 
TCT GG  
 
CTC CGG TTC TTG TCA ATG 
GT  
Estrogen 
Receptor/Esr2 
 
ACT GCC AAT CAT CGC 
TTC TC  
AGT AAC AGG GCT GGC ACA 
AC  
Insulin like Growth 
Factor 1/IGF1 
GGA CCA GAG ACC CTT 
TGC GGG G  
GGC TGC TTT TGT AGG CTT 
CAG TGG 
Progesterone 
Receptor/PR 
CCA GCA TGT CGT CTG 
AGA AA  
ACC ACA TCA GGC TCA ATG 
CT 
 
3.7.5 Analysis 
 cDNA amplification data was analyzed using Bio-Rad CFX manager software. 
Samples were assured for quality of target cDNA amplification with the use of the 
melting curve tool and amplification/Cq values. For each sample, the mean Cq value was 
calculated for the three PCR wells that contained the sample. The mean sample Cq value/ 
level of gene expression was then normalized to mean Cq value/expression level of the 
reference gene (B2M) from the same sample, resulting in a relative quantification value 
(see, formula 1). Relative quantification values were then statistically assessed based on 
animal treatment group. 
Formula 1: Relative quantification value for the normalization of target gene 
expression 
Relative quantification= 2-Cq  
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3.8 Statistical analysis 
 All statistical analysis was carried out with the use of SPSS statistical software 
version 22. Effect of chemical treatment was assessed for mean uterine weights, 
histological analysis of the ovary, immunohistochemical analyses in the ovary, and 
ovarian gene expression with the use of an ANOVA test followed by a Bonferroni Post 
Hoc test. Comparisons between oil vehicle and ethinyl estradiol treated females at 
PND22 were conducted with independent samples T-tests. Graphs were made in excel, 
and all graphs show mean ± SEM. Results were considered significant at p<0.05. 
Statistical trends were identified as p>0.05 but <0.10. 
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CHAPTER 4 
RESULTS 
 
4.1 Body and uterine weight 
 Body weight is a standard measure of animal health. In order to measure any 
significant decrease in animal health potentially induced by chemical treatment, body 
weight was measured before sacrifice at PND 22, 16 weeks and 24 weeks of age. No 
notable changes in animal body weights were observed for either of the chemical 
treatment groups in comparison to the control group or between chemical treatment 
groups at any of the three measured ages (data not shown).  
Wet (unblotted) uterine weight is a standard measure of estrogencity. To measure 
estrogenic effects induced by chemical exposure, wet uterine weight was recorded at 16 
and 24 weeks of age. Although we did not measure uterine weight at PND22, other 
measures of estrogenicity (i.e. height of the uterine epithelium, expression of lactoferrin, 
etc.) are being conducted in the Vandenberg laboratory by other researchers; the data 
from these analyses are forthcoming. At both 16 and 24 weeks of age, no significant 
changes in uterine weight were observed between the control and chemical treatment 
groups. However, an ANOVA with Bonferroni post hoc test revealed a significant 
difference between the BPS and TBBPA treated groups at 16 weeks of age (Figure 5A), 
with mean uterine weights of BPS treated animals (0.169 g) that were significantly 
heavier than the mean uterine weight of TBBPA treated animals (0.119g) (p=0.02). No 
significant changes in uterine weight were observed at 24 weeks of age (Figure 5B).  
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Since body weight was variable between individual animals, uterine weight: body 
weight ratio was calculated. No significant differences were observed between treatment 
groups for relative uterine weight at 16 or 24 weeks of age (Figure 5C,D).   
 
4.2 Ovarian cysts 
Ovarian cysts were determined based on gross morphology of the ovary during necropsy. 
At PND22, cysts were not observed in any females in any treatment group. However, by 
16 weeks, cysts were observed in 3/8 females treated with BPS, an increase compared to 
the frequency of cysts in the vehicle-treated controls (0/5, see Table 2). At 24 weeks of 
age, cysts were observed in all treatment groups but were more common in the TBBPA 
and BPS-treated females compared to controls (Table 2). 
 
Table 2. Frequency of ovarian cysts in females treated perinatally with test 
chemicals 
 
 Controls TBBPA BPS 
% with ovarian 
cysts at 16 weeks 
of age (n) 
0% (5) 0% (6) 37.5% (8) 
% with ovarian 
cysts at 24 weeks 
of age (n) 
18.2% (11) 28.6% (7) 25% (8) 
 
 
4.3 Open field behavior assessment  
 To assess potential changes in sexually dimorphic behaviors induced by chemical 
exposure, female offspring were assessed at 15 and 23 weeks of age for a variety of 
previously validated open field behaviors that provide information regarding sexual 
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dimorphic behavior.  Animals were scored by hand based on the following criteria in the 
open field test: number of rears on walls, number of rears in the center of the open field, 
number of crosses through the center of the apparatus, and time spent grooming 
(described in 3.4).  Additional criteria were scored by an automated system, Noldus 
software, at PND22, week 15, and week 23 and included the total distance covered (cm) 
by each mouse during the 5 minute trial, their mean velocity (cm/s), the percentage of 
time the animal was moving, and the percentage of time the animal spent in a 5cm by 
5cm square in the center of the open field. 
4.3.1 PND 22   
 The Noldus software was used to measure four aspects of behavior in the open 
field (Figure 6A). At this age, there were no significant differences between any 
treatment groups. 
4.3.2 Week 15 
 Significant changes in behavior were observed in four categories: center rears 
(p=0.032), wall rears (p=0.029), center crosses (p=0.041) and total rears (p=0.010). For 
all four categories, BPS-treated animals had increased measures compared to controls and 
TBBPA had decreased measures compared to controls, although these differences were 
not statistically significant (Figure 6B). Yet, in all four categories the specific behavior 
was significantly increased in BPS treated animals compared to TBBPA treated animals.   
  Using the Noldus software, four quantitative measures were compared between 
the three treatment groups, and similar trends were observed for distance travelled, 
average velocity, and time spent moving: BPS treated females were typically more active 
than controls, and TBBPA-treated females were typically less active than controls (Figure 
	
45	
6C)
not
gro
TB
eac
 
 
 
 
 
 
 
Fig
and
the
me
PN
han
Par
sof
me
pan
and
test
 
 
 
 
 
. Although 
 observed fo
up compare
BPA were s
h other. 
ure 6. Effec
 TBBPA ex
 open field.
asured by th
D22-24. B) 
d in female
ameters mea
tware at 15 w
asured by ha
els, a indica
 0.09, and *
. 
significant d
r either che
d to controls
ignificantly 
ts of develo
posures on
 A) Behavio
e Noldus so
Parameters 
s at 15 week
sured by th
eeks of ag
nd at 23 we
tes a p-valu
 p<0.05, Bo
ifferences w
mically-trea
, BPS and 
different fro
pmental B
 behaviors 
ral paramet
ftware at 
measured by
s of age. C)
e Noldus 
e. D) Param
eks of age. 
e between 0
nferroni pos
ere 
ted 
m 
PS 
in 
ers 
 
 
eters 
In all 
.05 
thoc 
46	
	
4.3.3 Week 23 
 No significant changes in behavior for the open field test were observed at 23 
weeks of age between any treatment groups. There was a trend for a decrease in the 
number of center crosses in the TBBPA-treated animals compared to control animals 
although this was not statistically significant (Bonferroni, control vs TBBPA, p=0.092, 
Figure 6D). The Noldus data has been collected but will be analyzed in the future. 
 
4.4 Ovarian follicle formation 
 Based on the hypothesis that BPS and TBBPA are able to induce estrogenic 
effects and thus induce premature ovarian development, we compared morphology of 
ovarian follicles at PND 22 and 16 weeks of age from animals developmentally exposed 
to vehicle, BPS and TBBPA. The method for follicle scoring is discussed in depth in 
section 3.5.  
4.4.1 PND 22 
 At PND 22, the follicle-score categories assessed included: primordial follicles, 
primary 1 follicles, primary 2 follicles, secondary follicles and antral follicles (described 
in detail in section 3.5). Follicles from every tenth section of the entire ovary as well as 
follicles from only four sections of the medullary region were scored separately to 
account for variability in ovarian size. Significant changes observed in follicle category 
numbers from the entire ovary are shown in Figure 7, and from four sections in Figure 8. 
 Results from the analysis of every tenth section of the ovary are described as 
follows: EE2 induced a significant increase in the number of oocytes throughout the 
entire ovary in control (p=0.037) and TBBPA (p=0.001) treated animals (Figure 7A), and 
	F
a
fo
b
 
igure 7. Ov
nd without 
llicles. C) T
etween 0.05
arian follicu
an EE2 cha
otal number
 and 0.09, an
lar param
llenge.  A) T
 of seconda
d * p<0.05,
47	
eters measu
otal numbe
ry follicles. 
 Bonferroni
red in entir
r of oocytes
 In all panel
 posthoc tes
e ovaries a
. B) Total nu
s, a indicate
t. 
 
t PND22 wi
mber of 
s a p-value 
th 
48	
	
 the number of follicles in control (p=0.024) and TBBPA (p=0.038) treated animals 
(Figure 7B). These effects induced by EE2 were not observed in BPS treated animals. EE2 
also induced a significant increase in the number of total secondary follicles in TBBPA 
treated animals (p=0.001) and in control animals (p=0.053, Figure 7C). Again, EE2 failed 
to increase the number of secondary follicles in BPS treated animals. An ANOVA 
revealed differences in the number of secondary follicles between control, BPS and 
TBBPA vehicle treated animals (p=0.082, Figure 7C). However, differences between 
specific treatment pairs were not identified. In summary, the EE2 challenge increased the 
number of total oocytes, secondary follicles and total number of follicles throughout the 
entire ovary in control and TBBPA, but not BPS, treated animals. 
 Results from analysis of four consecutive sections from the medullary region of 
the ovary are described as follows: An increase in oocytes in four sections was observed 
for control animals (p=0.054) treated with EE2 (Figure 8A). An ANOVA with Bonferroni 
post hoc analysis identified a significant difference between the number of oocytes in 
four sections between EE2 challenged control and BPS treated animals (p=0.026, Figure 
8A); the number of oocytes was significantly greater in the control group compared to 
BPS-treated females. Similar to the results above, EE2 challenge also induced significant 
increases in total number of follicles in four sections of control (p=0.04) and TBBPA 
(p=0.013) treated animals (Figure 8B), and the number of secondary follicles in four 
sections of control (p=0.016) and TBBPA (p=0.01) treated animals (Figure 8C). An 
ANOVA revealed a trend in changes to the number of secondary follicles in four sections 
between the three vehicle treatment groups (p=0.061) and a difference in the number of 
total follicles in four sections between the three EE2 treatment groups (p=0.092) however,  
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Table 3. Number of animals with MOFs visible in histological sections at PND22. 
 Control TBBPA BPS 
Postnatal 
vehicle 
0/4 1/5 1/4 
Postnatal 
EE2 
0/4 3/5 0/4 
 
4.4.2 Week 16 
 At 16 weeks of age, follicle-score categories assessed included: primordial 
follicles, primary 1 follicles, primary 2 follicles, secondary follicles, antral follicles and 
corpus lutea (described in detail in section 2.5, see also Figure 2). Follicles from every 
tenth section of the entire ovary as well as follicles from only four sections of the 
medullary region were scored separately to account for variability in ovarian size. No 
significant or notable changes in follicle scores were observed in relation to treatment at 
16 weeks of age for assessment of every tenth section or four sections of the ovary (data 
not shown).   
Again, we examined the 16 week ovaries for the presence of MOFs. At this age, 
MOFs were observed in all treatment groups including the controls (Table 4). 
 
Table 4. Number of animals with MOFs visible in histological sections at week 16. 
Control TBBPA BPS 
2/4 2/4 1/5 
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4.5.1 PND 22 
 EE2 induced a significant increase in Ki67 expression in primary 2 granulosa cells 
in BPS treated animals (p<0.001, Figure 11A). An ANOVA with Bonferoni post hoc test 
identified significant differences in Ki67 expression in primary 2 granulosa cells between 
the three EE2 challenged treatment groups; the expression of Ki67 in the BPS treated 
group was significantly increased compared to the control (p<0.001) and TBBPA 
(p<0.001) treated groups (Figure 11A). In contrast, EE2 induced a significant decrease in 
the level of Ki67 expression in secondary follicle theca cells and total theca cells in 
TBBPA treated animals (Figure 11B,C). Additionally, there were treatment related 
differences in ER expression of EE2 challenged animals for total percentage of ER 
positive granulosa cells, although these did not reach statistical significance (ANOVA, 
p=0.096, Figure 11D). Pairwise T-tests did not identify the differences between treatment 
groups.   
4.5.2 Week 16 
 There were no significant changes observed in Ki67 or ER expression at 16 
weeks of age for any of the follicle categories scored (data not shown). 
4.6 Analysis of ovarian gene expression via qPCR 
 To further quantify changes in ovarian development influenced by early life 
chemical exposure, several genes which are crucial for hormone regulation in the ovary 
were measured based on their expression levels in ovarian tissue with the use of qPCR. 
Changes in ovarian gene expression levels were assessed for the following six target gene  
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sequences: androgen receptor (AR), epidermal growth factor receptor (EGFR), estrogen 
receptor α (ER), estrogen receptor β (ER), insulin like growth factor1 (IGF1) and 
progesterone receptor (PR) (described in Section 2.8). 
4.6.1 PND 22 
 EE2 induced a significant decrease in EGFR and ER expression in animals 
exposed to BPS during prenatal development (p=0.003, Figure 12A, B). Significant 
 changes in EGFR expression based on prenatal treatment were also noted; BPS treated 
animals exposed to vehicle at pre-puberty had significantly higher levels of EGFR 
expression compared to control animals (Bonferroni, p=0.023) and TBBPA treated 
animals (p= 0.034, Figure 12A) also exposed to vehicle. A significant increase in ER 
expression levels was also observed in BPS treated animals compared to TBBPA treated 
animals (p=0.05, Figure 12B).  Significant differences based on treatment were not 
observed for AR (Figure 12C), ERα (Figure 12D), IGF1 (Figure 12E), or PR (Figure 
12F). 
4.6.2 Week 16 
 There were no significant or notable differences in ovarian gene expression at 16 
weeks of age for any of the genes examined (Figure 13).  
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CHAPTER 5 
DISCUSSION 
5.1 Body and uterine weight 
 Classic toxicological animal studies often assess risk associated with chemicals 
based on outcomes such as changes body weight, as this outcome is described in 
internationally recognized guideline studies (Catanese et al. 2015; Myers et al. 2009b) 
However, this measure is now viewed as an extreme health outcome since large doses of 
chemical are often needed to obtain a significant fluctuation in body weight. Here, 
significant changes in body weight of animals exposed to either BPS or TTBPA were not 
observed. Environmentally relevant, low-doses of chemical were administered in this 
study since BPS and TBBPA are suspected EDCs, and many modern EDC studies aim to 
examine doses below the toxicological no observed adverse effect level (NOAEL) 
(Vandenberg et al. 2012). Therefore, we did not expect to see changes in body weight as 
an outcome of chemical exposures since these classical signs of toxicity are only 
anticipated at higher doses.  
To our knowledge, studies assessing changes in rodent body weight as a result of 
BPS exposure have not yet been conducted or reported. However, it has been shown 
previously that no significant changes in body weight were observed in rats exposed to 
TBBPA or BPA postnatally (Choi et al. 2011) or perinatally (Bo et al. 2010; Tada et al. 
2006), although many other studies have shown increases in body weight and more 
sensitive measures of adiposity in rodents exposed to BPA during early development, 
reviewed in (Rubin and Soto 2009). Thus, assessments of the effects of EDCs on body 
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weight are complicated, and should consider whether weight gain and weight loss are 
both toxicologically relevant hazard assessment outcomes.  
 The uterus is particularly sensitive to estrogen since E2 is responsible for 
stimulating proliferation of the endometrium and enlargement of the uterine glands 
during normal reproductive cyclicity (Kovacs and Ojeda 2011). Recommended tests 
issued by the Endocrine Disrupter Screening and Testing Advisory Committee 
(EDSTAC) of the U.S. Environmental Protection Agency (U.S. EPA) include what is 
known as the “uterotrophic response assay” as the preferred in vivo screening method for 
measuring estrogenicity and anti-estrogenicity of chemicals in rodents (Padilla-Banks et 
al. 2001). This method is a part of “tier 1” of a two tiered testing protocol meaning that a 
positive uterotrophic assay would require further testing as a part of “tier 2” (Zoeller et al. 
2012). Briefly, this method compares wet weights of uteri from pre-pubertal female 
rodents exposed to a chemical of interest and compares the exposed uterine weights to the 
wet uterine weights from pre-pubertal females exposed to a known estrogenic compound 
such as EE2 (positive control). If the chemical of interest induces a significant increase in 
uterine weight, similar to that induced by the positive control, that chemical may then be 
categorized as an estrogenic compound. In an alternative version of the uterotrophic 
assay, animals may be ovariectomized, then exposed to a chemical of interest; if the 
uterine weight increases significantly, the chemical may then be categorized as an 
estrogenic compound.  In our study, we did not ovariectomize the animals, allowing us to 
preserve the ovaries for study, as uterine weight was not among the primary endpoints of 
interest. 
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 Unfortunately, we did not weigh the uteri collected from females at PND22. To 
overcome this, another student in the laboratory is measuring additional endpoints that 
are predictive indicators of estrogen exposure such as height of the uterine endometrium, 
volume fraction of the uterine compartments, and expression of estrogen-sensitive 
proteins such as lactoferrin (Vandenberg et al. 2006). These data are forthcoming. At 16 
weeks of age, we observed a significant change in uterine weight; animals exposed to 
BPS had significantly heavier uteri than animals exposed to TBBPA.  However, we did 
not account for estrous cycle stage, which can drastically influence uterine weight. Thus, 
our results could simply be due to differences in the estrous cycle stage when animals 
were killed. 
Further, because animal body weights varied, the relative uterine weight (uterine 
weight/body weight) was calculated for each animal to account for variability in body 
weight. No significant differences were observed for relative uterine weight for any 
treatment group. This could mean that the significant difference observed in absolute 
uterine weights between BPS and TBBPA treated animals may be attributed to 
differences in total body size, rather than specific effects of these compounds on uterine 
weight.  
 Previous studies show that prepubertal uteri are more sensitive to estrogen 
stimulation than uteri from adult animals (Kang et al. 2000; Padilla-Banks et al. 2001). 
Based on this information, it is possible that we did not observe significant changes in 
body/uterine weight ratios due to the age of the animals.  It has been previously shown 
that TBBPA exposure during the perinatal period did not induce changes in uterine to 
body weight ratios at PND27 in rats (Tada et al. 2006). Although we cannot say whether 
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or not changes in uterine weights would be induced by perinatal BPS or TBBPA 
exposure when organs were collected at PND 22, it is likely that pre-pubertal EE2 
treatment would induce an increase in uterine weight.  In fact, the timing of EE2 
treatment and the dose we utilized were both selected to induce a uterotrophic response; 
our major goal was to understand whether perinatal exposure to BPS or TBBPA would 
alter the estrogen-sensitive responses to this pubertal EE2 challenge. 
 Although the EPA currently uses the uterotrophic assay to assess estrogenicity 
and anti-estrogenicity of chemicals, this method has stirred debate from endocrine and 
environmental health experts who suggest that the method is not sensitive enough to 
reliably measure estrogen inference caused by environmental chemicals (Zoeller et al. 
2012). For example, chemicals with known endocrine disrupting properties at low doses 
including BPA and PCBs fail to induce uterotrophic response at the same low doses that 
induce other adverse health outcomes such as uterine tumors (Newbold et al. 2009; 
Rajapakse et al. 2002). The uterotrophic assay also fails to account for the increased 
sensitivity to estrogens after developmental exposures since fetal and neonatal exposures 
are not tested in this assay. Fetuses and neonates are more sensitive to environmental 
chemicals than adults, with effects often seen at doses hundreds or thousands of times 
lower than the doses required to observed uterotrophic responses in pubertal or adult 
ovariectomized animals (Markey et al. 2001), and see also discussion of the DOHaD 
hypothesis in section 1.5. It has been shown that fetal exposure to low doses of BPA 
results in adverse health effects later in life including preneoplastic mammary lesions that 
are not observed at high doses (Durando et al. 2007; Murray et al. 2007). Effects due to 
developmental and low dose chemical exposures are completely overlooked by 
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regulatory measures of estrogenicity by the endocrine disrupter screening program 
(EDSP). For these reasons, endocrinologists view the uterotrophic assay as unfit to 
optimally measure estrogenic effects induced by environmental chemicals (Zoeller et al. 
2012).   
 
5.2 Behavioral effects induced by perinatal chemical exposure 
 It has been shown previously that perinatal exposure to estrogenic chemicals such 
as BPA can induce alterations in the number of neurons and expression of genes in 
sexually dimorphic regions of the brain and thus lead to changes in sexually dimorphic 
behaviors in assays including the open field test (Patisaul et al. 2006; Rubin et al. 2006). 
Behavior data from open field tests in rodents suggest that females have a higher rate of 
activity in comparison to males (Archer 1975; Blizard et al. 1975).  Classical 
endocrinology studies revealed that the aromatization of testosterone to estrogen during 
fetal development is required for the development of male brain phenotypes in the male 
rodent; thus, exposures of estrogens to females during these critical periods of 
development can induce masculinization of these brain regions, and thus masculinization 
of behaviors observed in the open field (Ogawa et al. 1997; Simerly 1989). A previous 
study reported sexually dimorphic behaviors such as rears on wall, time spent in the 
center of the field, and time stopped, in control animals; however, in animals that were 
developmentally exposed to environmentally relevant doses of BPA, these sexually 
dimorphic behaviors vanished with similar behaviors observed in males and females 
(Rubin et al. 2006). This loss of sexual dimorphism appeared to be due to masculinization 
of female behaviors, and feminization of male behaviors. 
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 Although our experiments did not compare behaviors between male and female 
mice, our goal using the open field test was to identify potential differences in behavior 
induced by developmental chemical exposure that could be indicative of alterations to 
sexually dimorphic areas of the brain. The parameters measured in the open field test 
were specifically chosen to measure activity level of the animals, with the expectation 
that females exposed to exogenous estrogenic substances during development would 
display decreased activity in the open field test, indicating masculinization due to 
exposure.  
In contrary to the previously mentioned BPA study (Rubin et al. 2006), the 
behavioral data reported here do not suggest that females developmentally exposed to 
BPS exhibit masculinized behaviors in comparison to control females at 15 weeks of age. 
Instead, four parameters (center rears, wall rears, center crosses, total rears) suggest that 
animals exposed to BPS have increased activity in comparison to the control, consistent 
with hyperactivity. There is no evidence that we are aware of that behaviors in the open 
field can be “hyper-feminized”, although that conclusion is also consistent with our 
observations. 
In contrast to the effects of BPS, females exposed to TBBPA had decreased 
activity compared to the control. These findings could suggest that animals exposed to 
TBBPA are masculinized to some degree, although additional behavioral measurements, 
as well as investigations of sexually dimorphic regions of the brain, are also needed to 
support such a conclusion.  
Importantly, significant behavioral differences were not seen at 23 weeks of age, 
although a notable decrease in the number of center crosses induced by TBBPA exposure 
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compared to control animals could further support the hypothesis that developmental 
exposure to TBBPA results in masculinization to some degree. It is plausible that the 
behaviors observed in the open field were affected by the estrous cycle stage of the 
females, which was not controlled in our study at either 15 or 23 weeks of age. Again, 
additional study is needed here. 
 
5.3 Effects on ovarian follicle formation, protein expression, and gene expression in 
prepubertal animals (PND 22) 
 
 It has previously been reported that developmental exposure to estrogenic EDCs 
such as BPA and DES result in abnormal ovarian follicle formation (Hunt et al. 2012; Li 
et al. 2014; Rivera et al. 2011; Rodriguez et al. 2010; Wang et al. 2014). Based on the 
hypothesis that BPS and TBBPA induce estrogenic effects and thus induce premature 
ovarian development, we compared morphology of ovarian follicles at PND 22 from 
animals developmentally exposed to BPS and TBBPA with ovarian follicles from 
females exposed to oil only. Importantly, a critical part of our experimental design 
included a pre-pubertal estrogen challenge. One female from each litter was treated with 
oil and one was treated with 1 µg/kg/day EE2 for three days, from PND19-PND21. Prior 
studies have revealed that developmental exposures to EDCs including BPA alter the 
response of animals to hormonal or carcinogen challenges experienced later in life 
(Durando et al. 2007; Prins et al. 2007; Wadia et al. 2007).  
 Pairwise T-tests of follicle formation data revealed that EE2 induced significant 
follicular growth in TBBPA exposed and control animals at PND22 in the following 
categories: total number oocytes, total secondary follicles and total number of follicles. 
Follicular growth and/or development here is defined as the transition of primordial 
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follicles to any other type of follicle with increased maturity in regards to the follicle 
cycle (described in 1.4.1). We would expect to see an increase in follicular development 
induced by EE2 since increased estrogen levels play a crucial role in the onset of puberty. 
However, this induction of growth was not observed for animals exposed perinatally to 
BPS and challenged with EE2. Based on our results, developmental exposure to BPS 
alone induced follicular growth (observed in females at PND22 after pre-pubertal 
treatment with oil vehicle); this was in contrast to control and TBBPA treated animals, 
which required EE2 to induce follicular growth in the pre-pubertal period. Collectively, 
these results suggest that perinatal exposures to BPS induce premature development of 
the pre-pubertal ovary, and that additional estrogen exposures have no additive effect, 
further suggesting that developmental BPS exposures disrupt normal estrogen regulated 
pathways.  
Further statistical analyses revealed that the number of oocytes in four sections of 
ovary was significantly lower in BPS treated animals compared to control animals after 
an EE2 challenge. These data also support our conclusion that a pre-pubertal estrogen 
challenge provided by EE2 was not successful at increasing oocyte development in BPS 
treated animals. Since the dose of EE2 we selected simulates estrogen levels experienced 
during and after puberty, these data may suggest that the number of oocytes formed after 
puberty could be significantly reduced in BPS-treated animals; these results may indicate 
that BPS could pose a threat to the individual’s fertility since a decrease in the number of 
oocytes directly correlates to decreased chances of fertilization.  
Several published studies have reported significant changes in the number of 
specific types of ovarian follicles induced by developmental exposure to BPA in mice, 
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rats and lambs (Li et al. 2014; Rivera et al. 2011; Rodriguez et al. 2010; Wang et al. 
2014). All of the studies above observed a significant decrease in the number of 
primordial follicles after BPA exposure, which could be consistent with our results 
suggesting that BPS causes an increase in ovarian maturation; increased ovarian 
maturation would be expected to decrease the number of primordial follicles, although 
we did not observe this specific measure. In contrast to our findings, one study observed 
reduced numbers of primary, antral and total follicles in animals exposed to BPA 
prepubertally (Li et al. 2014). To our knowledge, no studies using developmental EDC 
exposures and a pre-pubertal estrogen challenge have been conducted using ovarian 
endpoints, making it difficult to make further comparisons with our study. 
 Although these results were not statistically significant, BPS-treated females had 
an increase in the numbers of secondary follicles compared to controls. Secondary 
follicles are a measure of follicular maturity; because follicular maturation does not 
normally occur until the onset of puberty, it may be concluded that BPS exposure alone 
can advance follicular maturity. This data is similar to that of others who reported 
increases in the number of growing follicles (primary and preantral) induced by 
developmental BPA and DES exposure, consistent with the hypothesis that early life 
exposures to estrogenic chemicals can stimulate the transition of primordial follicles to 
more mature follicles (Rivera et al. 2011; Rodriguez et al. 2010).  
Although time of puberty was not specifically recorded in these experiments, the 
increase in follicle maturation suggests that puberty and ovulation in animals exposed to 
BPS could possibly have been reached sooner than in control and TBBPA treated 
animals. It has been reported that developmental exposure to BPA induces early onset of 
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puberty in rodents (Nah et al. 2011; Nikaido et al. 2005; Wang et al. 2014). Increased 
urinary BPA concentrations have also been associated with early onset of puberty in 
humans (Caserta et al. 2014). 
 To further test the hypothesis that BPS and TBBPA are able to induce estrogenic 
signaling pathways that prematurely induce ovarian development, we compared gene 
and/or protein expression of factors that tightly regulate hormone action in the ovary at 
PND 22. Immunohistochemistry was used to measure the expression of Ki67, a marker of 
cell proliferation. EE2 treatment induced increases in the number of Ki67 positive 
granulosa cells in specific follicle types in the ovaries of BPS exposed animals. Further, 
these increases were significant when BPS treated animals were compared to either the 
control or TBBPA treated groups. These data were surprising because they do not appear 
to agree with the follicular data discussed above. Based on the follicle data, which 
showed that EE2 induced follicular development in the control and TBBPA but not BPS 
groups, we might expect to see no effect on measures of cell proliferation in animals 
exposed to BPS and challenged with EE2. Instead, our results suggest the possibility that 
the premature induction of ovarian development by BPS is independent of proliferation, 
or the more likely possibility that BPS induced a wave of proliferation prior to our 
assessment at PND22, and a second wave of proliferation is induced by the EE2 challenge 
in these BPS-exposed females. Our immunohistochemical proliferation results are 
somewhat consistent with previous studies that observed increased expression of Ki67 in 
granulosa cells of growing follicles after developmental exposures to BPA or DES 
(Rivera et al. 2011; Rodriguez et al. 2010).  
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In addition to our analysis of proliferation in granulosa cells, our 
immunohistochemical analysis revealed fewer Ki67 positive theca cells in secondary 
follicles and in the overall percentage of positive theca cells in TBBPA treated animals 
after an EE2 challenge. These results are contrary to a previous study that reported an 
increase in Ki67 expression in antral thecal cells as a result of BPA exposure. Our data 
suggest that, at least for some measures in the ovary, TBBPA exposures induce different 
effects than either BPA or BPS; our data, as well as results from a number of prior 
studies, are consistent with the hypothesis that both BPS and BPA act similar to estrogen. 
Thus, our data suggest that developmental exposures to TBBPA alters ovarian 
development via mechanisms that are distinct, and perhaps even independent of estrogen 
receptor signaling.  
 Both immunohostochemistry and qPCR analyses were used to quantify the 
expression of ER, one of the two main types of nuclear receptor activated by estrogen to 
mediate estrogenic effects in ovarian follicles (Peretz et al. 2012). Although qPCR is 
widely accepted as a reliable measure to quantify gene expression, 
immunohistochemistry was performed to allow visualization of potential changes in ERα 
expression in specific types of cells and follicles. Our analyses revealed that EE2 induced 
an increase in the percentage of ER positive granulosa cells in animals exposed to BPS, 
although this increase was not statistically significant. Further, ovaries from animals 
exposed to BPS with and without an EE2 challenge showed a trend of increased ER 
expression in many follicle categories compared to control and TBBPA treated groups. 
However, no significant changes in ER expression were observed with qPCR.  Previous 
studies examining ER expression via immunohistochemistry and qPCR after BPA 
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exposures have shown similar mixed findings; some studies demonstrate increased ER 
expression after BPA exposure (Rodriguez et al. 2010) while others did not observe any 
changes in ER expression induced by BPA (Rivera et al. 2011; Veiga-Lopez et al. 
2013). Yet, these prior studies may shed light on how an estrogenic compound can 
influence ER protein expression, measured by immunohistochemistry, and not influence 
expression of the ER gene, Esr1. In-vitro timecourse experiments have shown that the 
effects of BPA on ER expression are time dependent; these studies have also concluded 
that BPA does not mediate follicular growth through ER, but via disruptions to other 
aspects of the cell cycle (Peretz et al. 2012). In fact, ER itself has been shown to play 
little or no role in follicular development parameters (Hegele-Hartung et al. 2004).     
 The other main nuclear receptor that regulates estrogenic effects in ovarian 
follicles and drives granulosa cell proliferation is ER (Peretz et al. 2012). We observed 
that perinatal exposure to BPS increased ER expression (Esr2) in the whole ovary 
compared to control and TBBPA treated animals. Yet, EE2 challenge caused a decrease 
in Esr2 expression in BPS-treated females. This data may help explain the results we 
observed for the effects of BPS on follicular data discussed above, where BPS exposure 
increased the number of advanced follicles. An increase in ER expression is consistent 
with an increase in follicle growth (Peretz et al. 2012). Our findings also agree with prior 
studies which revealed an increase in ovarian ER expression as a result of BPA 
exposure (Brieno-Enriquez et al. 2012; Peretz et al. 2012; Rodriguez et al. 2010). Some 
previous studies have concluded that BPA acts as an ER antagonist, and via these 
actions can disturb ovarian follicular development (Brieno-Enriquez et al. 2012; Hunt et 
al. 2003; Susiarjo et al. 2007). In fact, it has been noted that ovarian meiotic defects 
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induced by developmental BPA exposure are nearly identical to those observed in ER 
knock-out mice, highlighting the crucial role of ER function in ovarian development 
(Susiarjo et al. 2007). Our findings mirror those induced by BPA, suggesting that BPS 
also acts as an estrogen antagonist and may be able to bind to ER, thus inducing 
downstream changes which result in the disturbance of ovarian follicular development. 
Finally, our findings agree with the hypothesis that ER mediates direct estrogen effects 
on ovarian follicular development (Hegele-Hartung et al. 2004). The antagonistic actions 
of BPS on ER could inhibit endogenous estrogen activation of ER, thereby disrupting 
negative feedback; ovarian cells may compensate for the loss of ER function by 
increasing ER expression, consistent with the increased Esr2 expression shown here.  
Similar to the ER expression results discussed above, BPS exposure also 
increased expression levels of epidermal growth factor receptor (EGFR) compared to 
control animals. It has been shown that EGFR expression increases late in 
folliculogenesis, consistent with our finding of increased numbers of mature follicles in 
BPS treated animals (El-Hayek et al. 2014). The increase in EGFR expression due to BPS 
exposure may have serious implications. Increased expression of EGFR is a characteristic 
of ovarian carcinoma; EGFR over expression is present in 25-50% of all ovarian cancers 
(Lafky et al. 2008). Our data suggests that BPS may have malignant effects in regard to 
ovarian development and poses a public health concern. Yet, importantly, treatment with 
an EE2 challenge decreased EGFR expression in BPS-treated animals.  
EGFR expression is critically regulated by E2; both estrogen and FSH stimulate 
EGFR expression in granulosa cells, and the LH surge that is responsible for ovulation 
releases ligands that activate EGFR in granulosa cells (El-Hayek et al. 2014; Garnett et 
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al. 2002). These factors suggest several plausible phenomena: First, BPS may be able to 
act as an estrogen to stimulate increased EGFR expression in granulosa cells. 
Alternatively, BPS may be able to induce an LH surge in BPS treated animals, which 
would further explain the increase in EGFR expression.  The observed effects induced by 
BPS exposure including increased EGFR and ER expression, in combination with data 
showing increased follicular maturation, go hand in hand; follicular growth is dependent 
on estrogen activation of ER and puberty induces follicular growth and increased EGFR 
expression in granulosa cells.  
 
 5.4 Effects on follicle formation, protein expression, and gene expression in adult 
animals (16 weeks) 
 
 In order to capture effects that develop later in life after developmental chemical 
exposure, the same criteria that were evaluated at PND 22 were also tested at 16 weeks of 
age. In contrast to the many effects observed in the ovary at PND22, few effects of BPS 
or TBBPA were observed in adulthood. At 16 weeks of age, no effects were observed on 
gene expression, cell proliferation, or follicle stages. Slight effects may exist for 
frequency of ovarian cysts, which was raised in BPS-treated animals compared to 
controls at this age. 
Previous studies that have examined developmental EDC exposure and related 
ovarian outcomes have largely failed to examine ovarian endpoints later in life. Instead, 
these studies have focused on ovarian development in fetal and/or prepubertal animals. 
This lack of historical information makes it difficult to interpret the data found here.  
Epidemiological studies focusing on precocious puberty induced by 
developmental exogenous estrogen exposures report varied negative health effects once 
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these affected individuals reach adulthood (reviewed in (Unuvar and Buyukgebiz 2012)). 
It is plausible that the adult age assessed here (16 weeks) was too young to see subtle 
effects on the reproductive system. We plan to assess tissue from 24-week-old animals 
from the same cohort in order to determine whether the significant changes observed at 
PND 22 correlate with additional changes at a time point even later in life. On the other 
hand, several rodent and epidemiological studies have found an association between EDC 
exposure and impaired fertility (Peretz et al. 2014; Souter et al. 2013). To our knowledge, 
to the effects of BPS or TBBPA on fertility or fecundity has not yet been explored; 
additional studies are needed to confirm actual effects on fecundity, such as reduced litter 
size, reduced numbers of litters, and altered time to achieve pregnancy (Cabaton et al. 
2011) .  
 The contrast in effects seen at PND 22 and week 16 may also be due to 
differences in circulating hormone levels before and after puberty. At PND 22, mice 
typically have not yet entered the pubertal window of development. During this window, 
sex steroid hormones are low and start to increase in preparation for the onset of puberty. 
With the very low production of estradiol prior to puberty (typically onset after PND25 in 
female mice), we can conclude that the effects seen at PND 22 were induced by an 
exogenous factor that has estrogenic function since the measured endpoints of interest 
were estrogen dependent. Yet, at the onset of puberty, the ovary produces estradiol, 
which initiates hormonal positive and negative feedback systems involving the ovary. It 
is plausible that significant changes were not observed at 16 weeks of age because 
endogenous estrogen levels were high enough to block the effects of early life BPS 
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exposures. Control and TBBPA treated animals at 16 weeks of age would be “caught up” 
in terms of sexual maturity and thus indistinguishable from animals treated with BPS.   
 
5.5 Future directions 
 Future experiments will include analysis of the outcomes measured above for 
animals of the same cohort at week 24 of age, focusing on follicular and gene expression 
changes. Measures of ovarian aging will also be assessed with the use of TUNEL assay 
for animals in each age group to quantify the number of apoptotic follicles induced by 
treatment and age. Developmental BPA exposure has been shown to increase the number 
of atretic follicles of the ovary (Li et al. 2014; Peretz et al. 2012; Rivera et al. 2011; 
Wang et al. 2014). Additional measures of gene expression for genes indicative of normal 
folliculargenesis including cyclin-dependent kinase (Cdk) inhibitor 1B (p27), and genes 
responsible for ovarian development including Cyp19, the enzyme responsible for the 
conversion of androgens into estrogens, and 5α-reductase, the enzyme responsible for the 
conversion of testosterone into dihydrotestosterone, could be analyzed. Expression of 
these genes in the ovary has been altered by developmental BPA exposure (Rivera et al. 
2011; Rodriguez et al. 2010; Veiga-Lopez et al. 2013) 
  As mentioned above, in the long-term, determining whether BPS and TBBPA 
alter measures of fertility and fecundity remains an important future research need. Not 
only do these measures represent obvious adverse outcomes, they suggest possible 
endpoints with public health implications. Further, analyses that examine additional 
aspects of the HPO axis including gene expression in the hypothalamus and pituitary will 
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also help to elucidate the mechanisms by which these compounds alter ovarian 
development and responsiveness. 
 
 
5.6 Conclusions 
 At the start of these experiments, it was not yet clear whether BPS or TBBPA 
should be considered endocrine disrupting chemicals. In the last year, a number of studies 
on BPS have suggested that developmental exposures to this compound induce altered 
health outcomes in rodents and zebrafish (Rochester and Bolden 2015). The results 
acquired through the experiments described here are fairly consistent with my initial 
hypotheses that developmental exposure to BPS and TBBPA 1) induce changes in 
estrogen-sensitive endpoints 2) disrupt cellular and molecular events in the developing 
ovary and 3) act as estrogens. 
  My results are consistent with hypothesis 1; BPS and TBBPA are able to induce 
changes in the ovary, an estrogen dependent endpoint. Hypothesis 1 is directly related to 
hypothesis 2 in that, changes in ovarian development induced by BPS and TBBPA were 
observed on both a cellular and molecular level. Majority of the cellular and molecular 
effects observed here were a result of BPS exposure. At the cellular level, these changes 
were most pronounced through the responsiveness of the ovary to a prepubertal estrogen 
challenge, which revealed that BPS induces premature ovarian development and alters 
the responsiveness of the ovary to EE2. At a molecular level, the estrogen challenge of 
animals exposed to BPS revealed that these animals are still responsive to estrogens and 
that this responsiveness may be mediated through ER, confirmed by qPCR data 
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showing elevated ER expression. The ability of BPS to act via ER confirms my final 
hypothesis of this chemical’s ability to act as an estrogen and therefore I would classify 
BPS as an EDC. TBBPA on the other hand appears to act through a different mechanism 
than BPS. Surprisingly, my study revealed that TBBPA also alters ovarian development 
on the molecular level; however, these effects may be independent of actions via the 
estrogen receptor. Majority of the molecular effects induced by TBBPA were observed in 
theca cells that primarily produce androstenedione for granulosa cells to convert to 
estradiol via aromatase. It is possible that TBBPA disrupts the production of androgens 
and thus the synthesis of estradiol without directly binding to estrogen receptors. This 
proposed mechanism of endocrine disruption induced by TBBPA is different than that of 
BPS however; endocrine function is modified in both cases.  
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